Sabinsa's flagship combination product, Curcumin C3 Complex® with BioPerine® (525mg/2.5 mg twice a day, 14 days), was used as adjuvant therapy for COVID-19 in a double-blind, randomized controlled clinical trial conducted on COVID-19 patients in India, where the wide-spread virus infection has strained the healthcare system.
Court Orders Prakruti to Pay over $1 Million in Fees and Costs to Sabinsa as a Sanction For Discovery Abuses in Litigation
- Details
- Press Release
- 1621

Sami-Sabinsa Group Limited, the world leader in Curcumin for the dietary supplements industry, has been awarded more than $1 Million in attorney’s fees and costs against Prakruti Products. The award, issued by a federal judge in New Jersey on May 24, came in the wake of Sabinsa’s successful prosecution of Prakruti’s egregious discovery misconduct. The Magistrate Judge had previously imposed non-monetary sanctions on Prakruti, and that ruling was affirmed by the District Judge on appeal. The award is Sabinsa’s latest win in a years-long discovery battle with Prakruti that began in June 2017, after the Court reopened a settled case involving Prakruti’s infringement of Sami-Sabinsa’s patented Curcumin C3 Complex®.
Sabinsa Founder Dr. Muhammed Majeed Named Father of Indian Nutraceuticals Industry by ASSOCHAM
- Details
- Press Release
- 1390

Dr. Muhammed Majeed, founder of the Sami-Sabinsa Group, was named the Father of Indian Nutraceuticals Industry with an honorary award presented on the occasion of ASSOCHAM’s virtual conference entitled Efficacy of Herbal Nutraceuticals: Stimulating the New Lifestyle.
New Research Published on Sabinsa’s Curcumin C3 Reduct® Supports Efficacy as an Oral Care Ingredient
- Details
- Press Release
- 1529

New research has recently been published that builds upon evidence from a previous trial investigating the potential of Sabinsa’s Curcumin C3 Reduct® ingredient in oral care applications.
Sabinsa Top Scientist Gives Presentation to U.S. FDA
- Details
- Press Release
- 1438

Dr. Kalyanam Nagabhushanam, President (R&D), Sabinsa Corporation presented, at the invitation of FDA, a seminar on December 10, 2020 to a group of US FDA scientists as part of the CDER Botanical Drug Seminar Series (BDSS).
Sabinsa Expands IP Portfolio with Five New U.S. Patents, Two CII Awards for IP Portfolio, and Dr. Majeed Honored by IASTAM
- Details
- Press Release
- 1403

Sabinsa ends the year with more good news about achievements. The Confederation of Indian Industry (CII) recognized the Sami-Sabinsa Group with two awards for IP property, and Sami-Sabinsa Founder and Chairman, Dr. Muhammed Majeed, was honored by the Indian Association for the Study of Traditional Asian Medicine (IASTAM). Additionally, the company has been granted five new U.S. patents, including strengthening IP protection on its flag-ship probiotic, LactoSpore® with new applications, and additional patents for novel compositions.
Sabinsa’s Macumax® Formula Demonstrates Vision Health Benefits in Published Study
- Details
- Press Release
- 1468

Sabinsa’s proprietary formulation Macumax® was shown to have vision health benefits in a clinical trial on subjects diagnosed with age-related macular degeneration (AMD). The study An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-Related Macular Degeneration authored by Muhammed Majeed, Shaheen Majeed and Kalyanam Nagabhushanam, was published in the Journal of Medicinal Food (ahead of print doi.org/10.1089/jmf.2020.0097).
© 2025 Sabinsa. All Rights Reserved | Disclaimer